Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration

NEXT STORY
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
PREV STORY
Intranasal Drug and Vaccine Market 2028 – Insights on Key Trends, COVID-19 Impact, Value Chain Analysis, Strategic Initiatives, and Future Outlook: Adroit Market Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG

author_avatar
NASDAQ Market News

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

author_avatar
NASDAQ Market News

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

author_avatar
NASDAQ Market News